Ascletis Pharma Reports First Patient Dosing with ASC30 in P-IIa Trial for Obese or Overweight Patients

Shots:Ascletis Pharma has dosed first participants with ASC30 (PO, QD) in its US P-IIa trial for obesity (BMI ≥30kg/m^2) or overweight pts (BMI ≥27kg/m^2 but <30kg/m^2) with ≥1 weight-related comorbidityTrial will assess 2 ASC30 formulations (tablets & tablets A1), with pts starting at 1mg & undergoing weekly titrations to maintenance doses of 20 or 40mg…

ByRidhi RastogiJuly 3, 2025

News

Processa Pharmaceuticals and Intact Therapeutics Enter Binding Term Sheet for PCS12852 Licensing Deal

Shots:Processa & Intact have entered into a binding term sheet for granting Intact an exclusive option to license PCS12852 for gastroparesis & other GI motility disordersAs per the deal, Processa will receive a 3.5% equity in Intact at closing, $2.5M option fee, ~$20M in development & regulatory milestones, ~$432.5M in commercial milestones, &…

ByRidhi RastogiJune 18, 2025

News

Skye Bioscience Enters a Formulation Development Agreement with Arecor Therapeutics for Nimacimab

Shots:Skye Bioscience has partnered with Arecor Therapeutics to develop a higher concentration formulation of Skye’s nimacimab, leveraging Arecor’s Arestat formulation platformAs per the deal, Skye will fund Arecor's development efforts, with the option to license rights of the new proprietary formulation & its intellectual property for further development & commercializationNimacimab (CB1 inhibitor,…

ByRidhi RastogiMay 19, 2025

Ascletis Pharma Reports First Patient Dosing with ASC30 in P-IIa Trial for Obese or Overweight Patients

Processa Pharmaceuticals and Intact Therapeutics Enter Binding Term Sheet for PCS12852 Licensing Deal

Skye Bioscience Enters a Formulation Development Agreement with Arecor Therapeutics for Nimacimab

Contact US

OUR INFORMATION

FOLLOW US